Mean serum zinc levels (μg/dL), proportion with low zinc levels (<65 μg/dL), and hematological indices at baseline and month-12 follow-up
| Zinc treatment arm and measure . | Baseline . | Month 12 . | P value∗ . |
|---|---|---|---|
| Zinc arm (N = 121) | |||
| Serum zinc, μg/dL, mean ±SD | 61.4 ± 11.5 | 72.2 ± 20.6 | .001 |
| Zinc deficient (<65 μg/dL), n (%) | 78 (64.5) | 50 (41.3) | .001 |
| Hematological indices | |||
| MCV, fL, mean ±SD | 78.7 ± 10.7 | 85.7 ± 10.2 | .001 |
| Hemoglobin, g/dL, mean±SD | 8.2 ± 1.3 | 8.1 ± 1.6 | .30 |
| Placebo arm (N = 117) | |||
| Serum zinc, μg/dL, mean ± SD | 62.9 ± 12.1 | 64.4 ± 12.6 | .32 |
| Zinc deficient (<65 μg/dL), n (%) | 71 (60.7) | 64 (54.7) | .32 |
| Hematological indices | |||
| MCV, fL, mean ±SD | 77.6 ± 8.9 | 83.8 ± 9.8 | .001 |
| Hemoglobin, g/dL, mean±SD | 8.3 ± 1.3 | 8.0 ± 1.3 | .02 |
| Zinc treatment arm and measure . | Baseline . | Month 12 . | P value∗ . |
|---|---|---|---|
| Zinc arm (N = 121) | |||
| Serum zinc, μg/dL, mean ±SD | 61.4 ± 11.5 | 72.2 ± 20.6 | .001 |
| Zinc deficient (<65 μg/dL), n (%) | 78 (64.5) | 50 (41.3) | .001 |
| Hematological indices | |||
| MCV, fL, mean ±SD | 78.7 ± 10.7 | 85.7 ± 10.2 | .001 |
| Hemoglobin, g/dL, mean±SD | 8.2 ± 1.3 | 8.1 ± 1.6 | .30 |
| Placebo arm (N = 117) | |||
| Serum zinc, μg/dL, mean ± SD | 62.9 ± 12.1 | 64.4 ± 12.6 | .32 |
| Zinc deficient (<65 μg/dL), n (%) | 71 (60.7) | 64 (54.7) | .32 |
| Hematological indices | |||
| MCV, fL, mean ±SD | 77.6 ± 8.9 | 83.8 ± 9.8 | .001 |
| Hemoglobin, g/dL, mean±SD | 8.3 ± 1.3 | 8.0 ± 1.3 | .02 |
Paired t-test used to compare continuous measures, McNemar’s chi-square test used to compare proportion with low zinc levels.